HALF MOON BAY, Calif., Sept. 21 /PRNewswire/ -- Saegis Pharmaceuticals, Inc., a biopharmaceutical company focused on developing medicines that protect and enhance memory and brain function, announced today that Jack M. Anthony has joined the company as senior vice president of Business Development. In this position, Anthony will oversee in-licensing and out-licensing opportunities and represent Saegis in interactions with potential partners. He will be reporting directly to Saegis' President and CEO, Rodney Pearlman, Ph.D.
"We are delighted to have Jack join the company," said Dr. Pearlman. "Saegis is building a powerful and focused pipeline to address a variety of cognitive disorders and Jack will be essential to our efforts to create strategic collaborations with major pharmaceutical companies that extend our development programs through later-stage clinical studies and product commercialization. His 31 years of experience in the healthcare industry will provide valuable and relevant insights to drive Saegis' growth and maturation."
Anthony most recently served as senior vice president of Business and Commercial Development at Tularik Inc. where he oversaw the company's business development initiatives. In the 13 years prior to Tularik, Anthony held senior level business development and marketing positions at FibroGen, Inc., Cell Therapeutics, Inc., Nektar and Applied Immune Sciences, Inc., completing numerous research, development and commercialization agreements with global pharmaceutical and life sciences companies. Anthony began his healthcare career at Baxter Healthcare in sales and marketing. Progressing through a number of domestic and international positions over eighteen years, Anthony departed Baxter as a vice president of the Blood Therapy Group.
"Coming to Saegis is a unique opportunity for me and I look forward to working closely with the Saegis team to achieve the company's partnership goals," said Anthony. "A growing number of us are facing cognitive impairment issues against which we have almost no truly effective medications. I believe Saegis' therapeutic development efforts have the potential to make a profound impact in this field and I am very pleased to be able to have a role in that effort."
About Saegis Pharmaceuticals
Founded in 1999, Saegis Pharmaceuticals is a pioneer in the development of medicines that protect and enhance the function of the human mind. Through licensing activity, development partnerships and internal discovery programs, Saegis Pharmaceuticals is building a portfolio of compounds with activity against a range of disorders of the brain and central nervous system, including Alzheimer's disease, mild cognitive impairment, and cognitive impairment associated with schizophrenia. Currently the Company has three orally-available small molecule compounds in clinical development, two of which have already demonstrated efficacy and safety in humans. Privately held, Saegis has received investment support from Versant Ventures, Technology Partners, Sofinnova Ventures (U.S.), Sofinnova Partners (Paris), Polaris Venture Partners, NeuroVentures, the Stanley Medical Research Institute and Novartis Pharma AG. For more information, visit http://www.saegispharma.com/ .
Saegis Pharmaceuticals, Inc.
(650) 560-0210 x259
Euro RSCG Life NRP
Saegis Pharmaceuticals, Inc.
CONTACT: Jack Anthony of Saegis Pharmaceuticals, Inc., +1-650-560-0210,x259, firstname.lastname@example.org; or Holli Kolkey of Euro RSCG Life NRP,+1-858-546-4811, email@example.com, for Saegis Pharmaceuticals, Inc.